Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report

Detalhes bibliográficos
Autor(a) principal: Mendes,Raquel R.
Data de Publicação: 2024
Outros Autores: Figueiredo,Pedro C., Andrade,Isabel
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452024000400054
Resumo: Abstract Introduction: Obinutuzumab is a type II anti-CD20 monoclonal antibody associated with a higher rate of toxicity when compared to rituximab. Gastrointestinal side-effects have been reported but data is still sparse. Case Presentation: A 47-year-old female with medical history of stage IV follicular non-Hodgkin lymphoma under chemotherapy presented with chronic bloody diarrhea and iron deficiency anemia. Endoscopic and histologic features resembled inflammatory bowel dis-ease (IBD), imposing a thorough differential diagnosis. The diagnosis of obinutuzumab-induced pancolitis was made and the drug was suspended with subsequent clinical improvement. Conclusion: This is the first case report of obinutuzumab-induced pancolitis. The challenging differential diagnosis of IBD required a multi-disciplinary approach with subsequent outcome and management implications.
id RCAP_866ab9c40bed94e2052d97e3d517ec2d
oai_identifier_str oai:scielo:S2341-45452024000400054
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case ReportObinutuzumabColitisInflammatory bowel diseaseAbstract Introduction: Obinutuzumab is a type II anti-CD20 monoclonal antibody associated with a higher rate of toxicity when compared to rituximab. Gastrointestinal side-effects have been reported but data is still sparse. Case Presentation: A 47-year-old female with medical history of stage IV follicular non-Hodgkin lymphoma under chemotherapy presented with chronic bloody diarrhea and iron deficiency anemia. Endoscopic and histologic features resembled inflammatory bowel dis-ease (IBD), imposing a thorough differential diagnosis. The diagnosis of obinutuzumab-induced pancolitis was made and the drug was suspended with subsequent clinical improvement. Conclusion: This is the first case report of obinutuzumab-induced pancolitis. The challenging differential diagnosis of IBD required a multi-disciplinary approach with subsequent outcome and management implications.Sociedade Portuguesa de Gastrenterologia2024-08-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/reporttext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452024000400054GE-Portuguese Journal of Gastroenterology v.31 n.4 2024reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452024000400054Mendes,Raquel R.Figueiredo,Pedro C.Andrade,Isabelinfo:eu-repo/semantics/openAccess2024-11-14T23:02:55Zoai:scielo:S2341-45452024000400054Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-11-14T23:02:55Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report
title Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report
spellingShingle Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report
Mendes,Raquel R.
Obinutuzumab
Colitis
Inflammatory bowel disease
title_short Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report
title_full Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report
title_fullStr Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report
title_full_unstemmed Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report
title_sort Obinutuzumab-Induced Inflammatory Bowel Disease-Like Pancolitis: A First Case Report
author Mendes,Raquel R.
author_facet Mendes,Raquel R.
Figueiredo,Pedro C.
Andrade,Isabel
author_role author
author2 Figueiredo,Pedro C.
Andrade,Isabel
author2_role author
author
dc.contributor.author.fl_str_mv Mendes,Raquel R.
Figueiredo,Pedro C.
Andrade,Isabel
dc.subject.por.fl_str_mv Obinutuzumab
Colitis
Inflammatory bowel disease
topic Obinutuzumab
Colitis
Inflammatory bowel disease
description Abstract Introduction: Obinutuzumab is a type II anti-CD20 monoclonal antibody associated with a higher rate of toxicity when compared to rituximab. Gastrointestinal side-effects have been reported but data is still sparse. Case Presentation: A 47-year-old female with medical history of stage IV follicular non-Hodgkin lymphoma under chemotherapy presented with chronic bloody diarrhea and iron deficiency anemia. Endoscopic and histologic features resembled inflammatory bowel dis-ease (IBD), imposing a thorough differential diagnosis. The diagnosis of obinutuzumab-induced pancolitis was made and the drug was suspended with subsequent clinical improvement. Conclusion: This is the first case report of obinutuzumab-induced pancolitis. The challenging differential diagnosis of IBD required a multi-disciplinary approach with subsequent outcome and management implications.
publishDate 2024
dc.date.none.fl_str_mv 2024-08-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452024000400054
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452024000400054
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452024000400054
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Gastrenterologia
publisher.none.fl_str_mv Sociedade Portuguesa de Gastrenterologia
dc.source.none.fl_str_mv GE-Portuguese Journal of Gastroenterology v.31 n.4 2024
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817548709622185984

Registros relacionados